PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction

Trial Profile

PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction

Phase of Trial: Phase II

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs Tadalafil (Primary)
  • Indications Benign prostatic hyperplasia; Duchenne muscular dystrophy; Erectile dysfunction; Pulmonary hypertension; Raynaud's disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Nov 2016 Status changed from not yet recruiting to recruiting.
    • 12 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top